From Surf Wiki (app.surf) — the open knowledge base

Stanford V

Stanford V (usually spoken as Stanford Five), is a chemotherapy regimen (with accompanying radiation therapy) intended as a first-line treatment for Hodgkin lymphoma. The regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens such as ABVD. The chemical agents used are:

A mustard derivative such as cyclophosphamide, chlormethine or ifosfamide
Doxorubicin, an anti-tumor antibiotic
Vinblastine, an alkaloid cell toxin
Vincristine, another alkaloid cell toxin
Bleomycin, another anti-tumor antibiotic
Etoposide, a DNA toxin
Prednisone, a corticosteroid

Drug Regimen

The chemotherapy part of Stanford V treatment can last anywhere from 8 to 12 weeks, depending on the staging of the disease. In many cases, this is followed by radiation therapy for anywhere from 2 to 6 weeks to the affected areas of the body.

Stanford V is a more rigorously administered form of chemotherapy, with treatments roughly twice as fast as those of other Hodgkin lymphoma treatments. However, in a randomized controlled study, Stanford V was inferior to ABVD.{{cite journal |title=ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi |journal=J. Clin. Oncol. |volume=23 |issue=36 |pages=9198–207 |year=2005 |pmid=16172458 |doi=10.1200/JCO.2005.02.907 | display-authors = 3 |doi-access=free |hdl=11380/3063 |hdl-access=free }} This study has been criticize for not adhering to the proper Stanford V protocol. Specifically, the radiation therapy component following chemotherapy was not properly administered in the Italian study. A retrospective study from the Memorial Sloan-Kettering Cancer Center displayed results similar to the Stanford Cancer Center's own experience. The study concluded that, "Stanford V with appropriate radiotherapy is a highly effective regimen for locally extensive and advanced HL."

Drug	Dose	Mode	Days
Doxorubicin	25 mg/m2	IV	Days 1 and 15
Vinblastine	6 mg/m2	IV	Days 1 and 15
Chlormethine	6 mg/m2	IV	Day 1
Vincristine	1.4 mg/m2 (max 2 mg)	IV	Days 8 and 22
Bleomycin	5 units/m2	IV	Days 8 and 22
Etoposide	60 mg/m2	IV	Days 15, 16
Prednisone	40 mg/m2	PO	Q2D

References

(1995). "Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report". J. Clin. Oncol..
(2010). "Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience.". Ann. Oncol..
"Cancer Care Ontario". Formulary.
Horning, SJ. (March 2000). "Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin's Disease: Eastern Cooperative Oncology Group Pilot Study E1492". Journal of Clinical Oncology.

Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

chemotherapy-regimens-used-in-lymphoma hodgkin-lymphoma

Want to explore this topic further?

Ask Mako anything about Stanford V — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report